A beyond-use date (BUD) marks the point after which a compounded preparation may no longer be dispensed or administered, and it sits at the center of nearly every FDA and state board inspection of a 503A/503B compounding pharmacy. USP <795> and USP <797>, revised effective November 1, 2023, set default BUD ceilings for preparations compounded without supporting data. Extending a BUD past those defaults is permitted, but only when the pharmacy holds formulation-specific stability data developed under specific testing conditions. When a compounder assigns a longer BUD without that specific support, the gap between the assigned date and the supporting record becomes the finding an inspector writes up.
Default Beyond-Use Dates Without Stability Data
Under USP <795>, nonsterile compounded preparations default to a BUD of 6 months for nonaqueous formulations (water activity below 0.6) and 14 days at controlled room temperature for water-containing formulations, absent supporting stability data, according to guidance summarized by Eagle Analytical and Fagron Academy. Sterile compounding operates under USP 797/800, and the revised USP <797> replaced the former low, medium, and high sterile risk-level framework with three categories tied to the compounding environment and testing performed. Category 1 preparations default to 12 hours at room temperature or 24 hours refrigerated. Category 2 preparations span 4 to 90 days depending on storage conditions and sterility testing performed. Category 3 preparations may reach up to 180 days when the pharmacy meets the chapter's environmental monitoring, personnel competency, and sterility testing requirements. Any longer BUD requires the pharmacy to produce that stability data on demand.
What Stability Data Must Show to Extend a BUD
USP <795> and <797> do not treat an extended BUD as a documentation formality. The stability study must use an analytical method that is stability-indicating and validated under USP <1225>, meaning it can distinguish the active ingredient from its degradation products. The study must be run on the exact formulation being dispensed, at the concentrations dispensed or on bracketing high and low concentrations, and packaged in the same container-closure system used in practice, with storage conditions during testing following ICH Q1A(R2). An extended Category 3 sterile BUD additionally requires particulate matter testing for injectable and ophthalmic products, container-closure integrity testing, and antimicrobial effectiveness testing under USP <51> for any preparation dispensed in multiple doses. 503B outsourcing facilities face a parallel obligation under cGMP: 21 CFR 211.166(a) requires a written stability testing program used to set expiration dates, generally following ICH Q1A(R2) long-term and accelerated testing intervals of about 12 and 6 months.
A beyond-use date longer than the USP default is only as defensible as the stability study behind it, not the professional judgment that assigned it.
Findings When Extensions Outrun the Data
Inadequate stability testing is one of the most frequently cited violations in FDA warning letters to compounding pharmacies. A peer-reviewed analysis of 141 warning letters issued to compounders between 2017 and 2022 found that 34 of them, about 24%, cited a firm's failure to establish a written stability testing program under 21 CFR 211.166(a), the regulation requiring firms to use stability data to set appropriate storage conditions and expiration dates. These findings follow a consistent pattern: the file contains no formulation-specific stability study, an outdated study, or one run on a different concentration, container, or storage condition than what is actually dispensed. FDA and state boards can treat that gap as adulteration or misbranding exposure under the Federal Food, Drug, and Cosmetic Act, and inspectors often expand the finding into a broader review of the pharmacy's Form 483 history. For guidance on responding once a finding escalates to a formal warning letter, see FDA Warning Letters to Compounders: The Response That Closes the File.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies and 503B outsourcing facilities promptly retain experienced healthcare defense counsel upon receiving a Form 483, warning letter, state board audit notice, or other government inquiry touching on beyond-use dating or stability documentation. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to government requests, avoid inadvertent admissions about the basis for an assigned BUD, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance represents 503A pharmacies and 503B outsourcing facilities in FDA inspections, Form 483 responses, warning letter matters, and state board proceedings involving beyond-use dating and stability documentation. The firm's attorneys work with compounders to assess whether existing stability data supports an assigned BUD before an inspector raises the question, and to build the record needed to defend it when one does. If your pharmacy has received an inspection finding or inquiry touching on beyond-use dates or stability testing, contact Health Law Alliance's compounding pharmacy defense team for a free, confidential consultation.
